Moodle
You are not logged in. (Login)
Skip Check this out...
Show or hide block

Check this out...

Welcome to E-Menai

20 mg of ambien Cambia, formulated with KPA's patented Dynamic Buffering Technology (DBT), was specifically developed to address widespread unmet needs among patients by offering fast and effective relief of migraine pain. For more information about APR, please visit www. disclaim any intent or obligation to update these forward-looking statements, and claim the protection of the Safe Harbor for forward-looking statements contained in the Act.

.


NewsA Level

Kowa Pharmaceuticals America, Inc., and a majority stake in the company was acquired by Kowa Company, Ltd.apr.ch., July 2 /PRNewswire-FirstCall/ -- Acura Pharmaceuticals, Inc. Acura and King are currently evaluating the FDA's Complete Response Letter, and at this stage believe they can respond to the issues raised without conducting any additional studies. Acura and King jointly developed Acurox Tablets and are developing three additional opioid analgesic product candidates utilizing Aversion(R) Technology pursuant to a 2007 License, Development and Commercialization Agreement..